What Makes Some Cancers More Aggressive Than Others? New Research Points to Cell Size

When people think about aggressive cancers, they often think about specific cancer types such as pancreatic, lung, or brain cancer. But emerging research suggests that the answer may be more complex. The behavior of a tumor may depend not only on where it originates, but also on the biological characteristics of the cancer cells themselves.

A recent study from researchers at Virginia Tech found that cancer cells with abnormal chromosome numbers can become especially aggressive when they are smaller in size. These cells were shown to grow faster, invade surrounding tissues more readily, and demonstrate greater resistance to common cancer treatments.

Why Chromosomes Matter

Healthy human cells typically contain 23 pairs of chromosomes that carry our genetic information. During cell division, errors can occur, resulting in cells with abnormal numbers of chromosomes. One such condition, known as tetraploidy, occurs when cells contain twice the normal number of chromosomes.

Tetraploidy has long been associated with cancer development and poor patient outcomes. However, researchers wanted to understand why some tetraploid cancer cells appear more dangerous than others.

A Surprising Discovery: Smaller Cells, Greater Risk

The study revealed that not all tetraploid cancer cells behave the same way. Even though they contained the same number of chromosomes, some cells were significantly smaller than others.

These smaller cells consistently demonstrated more aggressive characteristics:

  • Faster growth rates
  • Increased invasiveness
  • Greater tolerance to anti-cancer therapies
  • Enhanced ability to support tumor progression

Researchers also found that these patterns appeared across multiple cancer types, suggesting that cellular characteristics may sometimes be more predictive of tumor behavior than the cancer’s location in the body.

What This Means for Cancer Research

The findings highlight an important principle in modern oncology: cancer is driven by biological changes that occur at the cellular and molecular level long before symptoms appear.

Understanding these changes may help researchers identify individuals at higher risk, improve treatment strategies, and develop more personalized approaches to cancer care.

The Importance of Monitoring Biological Signals

While no single biomarker can predict cancer risk on its own, research increasingly shows that subtle changes within the body can provide valuable insights into health status and disease risk.

OneTest is built on this principle. By analyzing multiple cancer-related biomarkers and applying AI-powered risk assessment, OneTest is designed to identify biological patterns associated with increased cancer risk. Rather than focusing on a single marker, OneTest evaluates multiple signals simultaneously to provide a more comprehensive view of an individual’s health.

As scientists continue to uncover the factors that drive cancer development and progression, one thing is becoming clear: understanding biological changes earlier may create opportunities for more informed healthcare decisions and proactive health management.

References

Bloomfield M. et al. Cell and Nuclear Size Is Associated with Chromosomal Instability and Tumorigenicity in Cancer Cells That Undergo Whole Genome Doubling. Cancer Biology.

Bloomfield M. et al. Oxidative Stress and Serum Deprivation Influence the Evolution of Newly Formed Tetraploid Cells During Tumorigenesis. Proceedings of the National Academy of Sciences (PNAS).

Cancer Isn’t Just a Disease of Older Adults — Here’s What the Numbers Are Telling Us

For decades, cancer was largely thought of as something that happened to older adults. But that assumption is being challenged — not just by statistics, but by the doctors treating patients every day.

Oncologists across the country are reporting something that would have seemed unusual a generation ago: more of their patients are in their 30s and 40s. More are working. More are raising young children. And more are facing a diagnosis they never expected to receive so soon.

So what’s going on?


The Numbers Are Clear — Even If the Cause Isn’t

According to the American Cancer Society, the number of early-onset cancer cases — defined as cancer diagnosed in adults under 50 — is climbing by roughly 1 to 2 percent every year. A global health data analysis published in the journal BMJ Oncology projects that early-onset cancers will increase by around 30 percent between 2019 and 2030.

Oncologists at the University of Chicago Medicine say they’re seeing this shift directly in their clinics. More patients in their 30s and 40s are being treated for breast cancer, colorectal cancer, and head and neck cancers than in previous years.

High-profile cases have brought public attention to the trend — but behind the headlines, researchers are still working to understand why it’s happening.


What Might Be Driving the Rise?

There is no single confirmed cause. As oncologist Dr. Adam DuVall of UChicago Medicine has noted, the increase is likely the result of multiple factors working together — possibly lifestyle-related, environmental, or both. Current research points to four key areas:

Chronic inflammation The body’s inflammatory response — triggered by low physical activity, obesity, chronic stress, prolonged infections, or ongoing exposure to toxins — may be creating conditions that allow cancer cells to develop and spread more easily.

Gut microbiome disruption The trillions of bacteria living in the human gut play a critical role in regulating immunity and digestion. When that balance is disturbed — potentially by processed foods, microplastics, or other modern exposures — tumors may find it easier to take hold.

Reproductive and hormonal factors Trends toward having children later in life and having fewer children are associated with a modestly higher risk for certain hormone-sensitive cancers, including breast, ovarian, and endometrial cancers.

Healthcare disparities Unequal access to care, nutritious food, and timely medical treatment means that for many people, cancer is more likely to be caught late — or not at all until it has progressed.


The Screening Gap: A Problem That Goes Unnoticed

One of the most overlooked dimensions of this trend is what experts call the screening gap. Standard cancer screening guidelines were built around older populations. Colonoscopies are typically recommended starting at 45. Many other screenings have similar age thresholds.

That means a 38-year-old with early-stage colorectal cancer may have no routine test scheduled to catch it. By the time symptoms appear, the disease may have already advanced.

Dr. Nita Karnik Lee, a gynecologic oncologist at UChicago Medicine, emphasizes that people of all ages should be proactive. If something feels wrong, don’t wait. If cancer runs in your family, talk to your doctor about earlier screening. Symptoms that seem minor — unexplained fatigue, unexpected weight changes, persistent bloating, unusual lumps — deserve medical attention, not dismissal.

“It’s important to identify those warning symptoms and give them attention as soon as possible,” Dr. Lee has said. “If you have a family history of cancer, you may need to get screened sooner. We want patients to advocate for themselves.”


What You Can Do Right Now

While researchers continue to study the causes, there are meaningful steps every adult under 50 can take today:

  • Know your family history. Hereditary cancer risk is real. If a parent, sibling, or close relative was diagnosed — especially at a young age — share that information with your doctor.
  • Don’t ignore symptoms. Persistent, unexplained changes in your body are worth investigating. Early detection consistently leads to better outcomes.
  • Ask about earlier screening. If you have risk factors, you don’t have to wait until the standard screening age. Ask your physician whether earlier testing makes sense for you.
  • Consider a multi-cancer early detection test. Tools designed to screen for multiple cancer types from a single test are becoming an important part of proactive healthcare for adults of all ages.

Early Cancer Risk Detection Is the Difference

The rising rate of cancer in young adults is a signal worth taking seriously. But it doesn’t have to be a reason for fear. For the vast majority of cancers, outcomes are significantly better when the disease is found early — before symptoms appear, before it spreads, and while treatment options are most effective.

That’s the principle behind OneTest. A single test designed to detect early cancer risk across multiple cancer types — because cancer doesn’t wait, and neither should you.

Learn more at onetestforcancer.com


Source: UChicago Medicine, “Why are more young people getting cancer? What to know as cases rise,” August 2024. uchicagomedicine.org

This article is intended for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for guidance specific to your health situation.

Giant Pharmacist

Giant Foods Pharmacy Offering OneTest to Customers

Giant Food’s Cancer Screening Initiative using OneTest

In this interview with Pharmacy Times®, Rosa Lee, pharmacy manager with Giant Food Pharmacy, discusses a new cancer screening using 20/20’s OneTest to empower patients to manage their health better and shift towards preventative care. Lee explained how Giant’s cancer screening is transforming what community pharmacy can offer patients.

Click here to read more and watch the video.

 

 

Let our AI guide you to earlier cancer detection.

What does AI mean for healthcare?   AI in healthcare does what AI does everywhere else – it looks for complex patterns and organizes them based on common features. OneTest doesn’t look for a single determinant feature of cancer (for example, just one high biomarker value) it looks at the biomarker values, age and gender of the patient as a whole and looks for patterns associated with cancer in our expansive dataset. This approach helps our test be up to 98% accurate for those with an elevated risk for cancer.   How is AI incorporated in OneTest?   OneTest was shown the biomarker patterns for 27,938 patients as well as clinical factors like their age and gender. They were all healthy and asymptomatic, but some went on to develop cancer in a 12-month period. OneTest took note of the patterns seen in the individuals who went on to be diagnosed with cancer and how that correlated to when they were diagnosed. OneTest has seen the “face of cancer” and can help recognize it in a crowd!   How do we know it works?   This technology seems new, but that doesn’t mean it is “inaccurate”. In fact, OneTest has the highest detection rate of all available MCEDs for a number of common cancers. OneTest has been used in cancer detection for fire departments since 2018. Validation data shows OneTest performs similarly to how it did on the training dataset with East Asian, Western European and North American populations. While we can’t share individual and identifiable data, we have followed up on patients who were able to catch their cancer early with the help of OneTest.   If you still have questions, you can submit a contact form below to get in touch with a Clinical Testing Specialist!

← Back

Thank you for your response. ✨

       
illustration of a Man sitting down holding a Prostate cancer ribbon in his hands

Spreading Awareness Beyond Prostate Cancer Month

illustration of a Man sitting down holding a Prostate cancer ribbon in his hands

Introduction

September is National Prostate Cancer Awareness Month, which serves to shed light on the individuals affected by prostate cancer and the importance of early prostate cancer screening. During the month of September and every month following, we should to increase our efforts to educate men about the dangers of Prostate Cancer when it goes undetected. Every year, over 280,000 Americans are diagnosed with prostate cancer, and over 34,000 men die from it. The good news is that prostate cancer is highly treatable if detected early, so it’s crucial to spread awareness and encourage all men over 45 to get screened regularly, especially those who have a family history of prostate cancer. 

Who is At-Risk for Prostate Cancer?

Prostate cancer is the second most common cancer among men in the United States, after skin cancer. All men over 45 are considered at risk, and despite advances in screening and treatment, Prostate cancer still poses a significant health threat to the male population. The primary risk factors for developing prostate cancer are age, family history, and ethnicity. Specifically, Black men are at higher risk of developing prostate cancer than other men. They are also more likely to be diagnosed with advanced prostate cancer and have a higher mortality rate.

The Importance of Prostate Cancer Screening

Prostate cancer screening is essential to detecting the disease early before it spreads beyond the prostate gland. The most common screening test is the prostate-specific antigen (PSA) blood test. The PSA level in the blood can indicate if there is an elevated risk of prostate cancer.

The Benefits of Regular PSA Screening

PSA screening plays a primary role in the early detection of prostate cancer, particularly in healthy, symptom-free men. Prostate-specific antigen (PSA), the marker that is screened for, is a protein produced in the prostate and secreted into the blood. An elevated level of PSA in the blood may indicate the presence of prostate cancer but also is a sign of inflammation or infection. Men with prostate cancer may not be aware of changes in their prostate health, as symptoms may not present immediately, which makes regular PSA screening crucial. By routinely checking PSA levels, potential abnormalities can be identified at an early stage, which leads to better treatment and a higher survival rate.

The Limitations of traditional PSA Screening

Although a valuable test for prostate cancer screening, the traditional PSA test has some limitations. For one, traditional PSA screening is only around 60 to 70 percent specific in detecting prostate cancer, meaning that 30 to 40 percent of results may turn out to be inaccurate. This is known as a false positive or false negative result and can lead to inadequate treatment or a missed diagnosis. Additionally, the sensitivity (rate of detection) for a traditional PSA screening ranges from 9 to 33 percent, meaning that the test does not detect most prostate cancers that are diagnosed later on.

Because there is some variability with the results, the test may need to be repeated in order to be confirmed. Therefore, it is essential to have a more specific screening method that offers better accuracy and reliability in cases of prostate cancer.

How OneTest Improves Current PSA Screening

The benefit of using OneTest as an enhanced PSA screening test is that it provides near-perfect detection for prostate cancer. In real-world cancer studies, The Onetest cancer screening algorithm helped detect every single case of prostate cancer in healthy, symptom-free individuals. OneTest is not a replacement for regular cancer screening but can serve as an excellent supplement. Using our A.I. algorithm and our patented testing approach, OneTest can maximize the odds of an early diagnosis.

With OneTest, you can have peace of mind knowing that you are receiving the most advanced and reliable screening available and increasing your chances of early detection for prostate cancer and more than 20 forms of cancer.

Lifestyle Changes that Can Affect Prostate Screening Outcomes

In addition to screening, there are several lifestyle changes that men can make to reduce their risk of prostate cancer. These include maintaining a healthy weight, exercising regularly, eating a diet rich in fruits and vegetables, and limiting the intake of red and processed meat. It is also essential to avoid smoking and excessive alcohol consumption. 

Conclusion

Prostate Cancer Awareness Month provides an opportunity to spread awareness and encourage men to take charge of their health. If you are over 45 years old and/or have a family history of prostate cancer, it is crucial to get screened regularly. OneTest offers a more advanced and reliable screening method that can detect prostate cancer early when it is more treatable. It is also crucial to maintain a healthy lifestyle to reduce your risk of developing prostate cancer. By taking these steps, we can save lives and help end prostate cancer once and for all.

Supercharge Your PSA Screening today. Click below to Purchase OneTest